Literature DB >> 18778366

Leishmania donovani infection down-regulates TLR2-stimulated IL-12p40 and activates IL-10 in cells of macrophage/monocytic lineage by modulating MAPK pathways through a contact-dependent mechanism.

Dinesh Chandra1, Sita Naik.   

Abstract

The failure of Leishmania, an intracellular pathogen, to stimulate a pro-inflammatory response following entry into macrophages has been well reported. This occurs in spite of the fact that ligands for the toll-like receptors (TLR) have been recently shown on the parasite surface and their role in disease protection well documented. The outcome of infection in leishmaniasis is determined by the Th1 versus Th2 nature of the effector response and the generation of IL-12 and IL-10 by the infected macrophages is important for this decision. We evaluated the effect of L. donovani infection of monocytes (cell line THP-1, and monocytes derived from human peripheral blood) on Pam3cys (TLR2 ligand) and lipopolysaccharide (TLR4 ligand) stimulated production of IL-12p40 and IL-10. L. donovani infection caused suppression of TLR2 and TLR4-stimulated IL-12p40, with an increase in IL-10 production. Parasites also modulated the TLR2-stimulated mitogen-activated protein kinase (MAPK) pathway by suppressing MAPK P(38) phosphorylation and activating extracellular regulated kinase (ERK)1/2 phosphorylation. These effects could be reversed either by using a MAPK P(38) activator, anisomycin, or ERK1/2 inhibitor, U0126. L. donovani caused modulation of TLR2-stimulated MAPK pathways in a contact-dependent mechanism. In addition parasite structural integrity but not viability was required for suppression of TLR2-stimulated IL-12p40 and activation of IL-10. These observations suggest that L. donovani has evolved survival strategies that subvert the pro-inflammatory response generated through TLRs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18778366      PMCID: PMC2612710          DOI: 10.1111/j.1365-2249.2008.03741.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  46 in total

1.  RNA interference reveals a role for TLR2 and TLR3 in the recognition of Leishmania donovani promastigotes by interferon-gamma-primed macrophages.

Authors:  Jean-Frédéric Flandin; Frédéric Chano; Albert Descoteaux
Journal:  Eur J Immunol       Date:  2006-02       Impact factor: 5.532

2.  Dynamic and transient remodeling of the macrophage IL-10 promoter during transcription.

Authors:  Xia Zhang; Justin P Edwards; David M Mosser
Journal:  J Immunol       Date:  2006-07-15       Impact factor: 5.422

Review 3.  New players in TLR-mediated innate immunity: PI3K and small Rho GTPases.

Authors:  Monica Ruse; Ulla G Knaus
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

4.  Activation of the MAPK, ERK, following Leishmania amazonensis infection of macrophages.

Authors:  Ziyan Yang; David M Mosser; Xia Zhang
Journal:  J Immunol       Date:  2007-01-15       Impact factor: 5.422

5.  Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice.

Authors:  H T Lu; D D Yang; M Wysk; E Gatti; I Mellman; R J Davis; R A Flavell
Journal:  EMBO J       Date:  1999-04-01       Impact factor: 11.598

Review 6.  Visceral leishmaniasis (kala-azar): challenges ahead.

Authors:  R K Singh; H P Pandey; S Sundar
Journal:  Indian J Med Res       Date:  2006-03       Impact factor: 2.375

7.  Leishmania promastigotes activate PI3K/Akt signalling to confer host cell resistance to apoptosis.

Authors:  Aaron Ruhland; Nicole Leal; Peter E Kima
Journal:  Cell Microbiol       Date:  2006-08-02       Impact factor: 3.715

8.  Altered tyrosine phosphorylation of ERK1 MAP kinase and other macrophage molecules caused by Leishmania amastigotes.

Authors:  A Martiny; J R Meyer-Fernandes; W de Souza; M A Vannier-Santos
Journal:  Mol Biochem Parasitol       Date:  1999-07-30       Impact factor: 1.759

9.  The role of mannose receptor during experimental leishmaniasis.

Authors:  Oleg E Akilov; Rachel E Kasuboski; Cristina R Carter; Mary Ann McDowell
Journal:  J Leukoc Biol       Date:  2007-01-29       Impact factor: 4.962

Review 10.  T helper (h)1/Th2 and Leishmania: paradox rather than paradigm.

Authors:  James Alexander; Karen Bryson
Journal:  Immunol Lett       Date:  2005-02-17       Impact factor: 3.685

View more
  55 in total

1.  Infection of neutrophil granulocytes with Leishmania major activates ERK 1/2 and modulates multiple apoptotic pathways to inhibit apoptosis.

Authors:  Arup Sarkar; Eresso Aga; Uta Bussmeyer; Asima Bhattacharyya; Sonja Möller; Lars Hellberg; Martina Behnen; Werner Solbach; Tamás Laskay
Journal:  Med Microbiol Immunol       Date:  2012-06-03       Impact factor: 3.402

2.  A network map of Interleukin-10 signaling pathway.

Authors:  Renu Verma; Lavanya Balakrishnan; Kusum Sharma; Aafaque Ahmad Khan; Jayshree Advani; Harsha Gowda; Srikanth Prasad Tripathy; Mrutyunjay Suar; Akhilesh Pandey; Sheetal Gandotra; T S Keshava Prasad; Subramanian Shankar
Journal:  J Cell Commun Signal       Date:  2015-08-08       Impact factor: 5.782

3.  Activation of phosphatidylinositol 3-kinase/Akt and impairment of nuclear factor-kappaB: molecular mechanisms behind the arrested maturation/activation state of Leishmania infantum-infected dendritic cells.

Authors:  Bruno Miguel Neves; Ricardo Silvestre; Mariana Resende; Ali Ouaissi; Joana Cunha; Joana Tavares; Inês Loureiro; Nuno Santarém; Ana Marta Silva; Maria Celeste Lopes; Maria Teresa Cruz; Anabela Cordeiro da Silva
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

4.  Leishmanicidal effects of amphotericin B in combination with selenium loaded on niosome against Leishmania tropica.

Authors:  Mahshid Mostafavi; Saeedeh Farajzadeh; Iraj Sharifi; Payam Khazaeli; Hamid Sharifi
Journal:  J Parasit Dis       Date:  2019-01-01

5.  A chemical inhibitor of heat shock protein 78 (HSP78) from Leishmania donovani represents a potential antileishmanial drug candidate.

Authors:  Sonali Das; Anindyajit Banerjee; Mohd Kamran; Sarfaraz Ahmad Ejazi; Mohammad Asad; Nahid Ali; Saikat Chakrabarti
Journal:  J Biol Chem       Date:  2020-05-29       Impact factor: 5.157

6.  The Potent ITK/BTK Inhibitor Ibrutinib Is Effective for the Treatment of Experimental Visceral Leishmaniasis Caused by Leishmania donovani.

Authors:  Sanjay Varikuti; Greta Volpedo; Noushin Saljoughian; Omar M Hamza; Gregory Halsey; Nathan M Ryan; Bren E Sedmak; Gabriella R Seidler; Tracey L Papenfuss; Steve Oghumu; Abhay R Satoskar
Journal:  J Infect Dis       Date:  2019-01-29       Impact factor: 5.226

7.  Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1.

Authors:  Budhaditya Mukherjee; Rupkatha Mukhopadhyay; Bijoylaxmi Bannerjee; Sayan Chowdhury; Sandip Mukherjee; Kshudiram Naskar; Uday Sankar Allam; Dipshikha Chakravortty; Shyam Sundar; Jean-Claude Dujardin; Syamal Roy
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-22       Impact factor: 11.205

8.  Mechanisms of immune evasion in leishmaniasis.

Authors:  Gaurav Gupta; Steve Oghumu; Abhay R Satoskar
Journal:  Adv Appl Microbiol       Date:  2013       Impact factor: 5.086

9.  Cross-resistance of Leishmania infantum isolates to nitric oxide from patients refractory to antimony treatment, and greater tolerance to antileishmanial responses by macrophages.

Authors:  Tatiana R de Moura; Micheli Luize Barbosa Santos; Juciene M Braz; Luis Felipe V C Santos; Matheus T Aragão; Fabricia A de Oliveira; Priscila L Santos; Ângela Maria da Silva; Amélia Ribeiro de Jesus; Roque P de Almeida
Journal:  Parasitol Res       Date:  2016-02       Impact factor: 2.289

Review 10.  Leishmania interferes with host cell signaling to devise a survival strategy.

Authors:  Suvercha Bhardwaj; Neetu Srivastava; Raki Sudan; Bhaskar Saha
Journal:  J Biomed Biotechnol       Date:  2010-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.